Thus, Deltaflexin3 combineswith the approved PKG2 activator Sildenafil to more potently inhibitPDE6D/K-Ras binding, cancer cell proliferation, and microtumor growth.As observed previously, inhibition of Ras trafficking, signaling,and cancer cell proliferation remained overall modest. Here, KRAS is linked to cancer.